Annual CFF
$394.50 M
+$28.84 M+7.89%
31 December 2023
Summary:
Apellis Pharmaceuticals annual cash flow from financing activities is currently $394.50 million, with the most recent change of +$28.84 million (+7.89%) on 31 December 2023. During the last 3 years, it has fallen by -$297.68 million (-43.01%). APLS annual CFF is now -43.01% below its all-time high of $692.18 million, reached on 31 December 2020.APLS Cash From Financing Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly CFF
$2.54 M
-$39.95 M-94.02%
30 September 2024
Summary:
Apellis Pharmaceuticals quarterly cash flow from financing activities is currently $2.54 million, with the most recent change of -$39.95 million (-94.02%) on 30 September 2024. Over the past year, it has dropped by -$3.20 million (-55.76%). APLS quarterly CFF is now -99.37% below its all-time high of $403.27 million, reached on 31 March 2020.APLS Quarterly CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM CFF
$149.33 M
-$3.20 M-2.10%
30 September 2024
Summary:
Apellis Pharmaceuticals TTM cash flow from financing activities is currently $149.33 million, with the most recent change of -$3.20 million (-2.10%) on 30 September 2024. Over the past year, it has dropped by -$233.14 million (-60.96%). APLS TTM CFF is now -83.11% below its all-time high of $884.09 million, reached on 30 June 2020.APLS TTM CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
APLS Cash From Financing Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +7.9% | -55.8% | -61.0% |
| 3 y3 years | -43.0% | +19.9% | +923.1% |
| 5 y5 years | +199.1% | -98.7% | -61.6% |
APLS Cash From Financing High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | -43.0% | +7.9% | -99.3% | +115.9% | -80.5% | +923.1% |
| 5 y | 5 years | -43.0% | +199.1% | -99.4% | +115.9% | -83.1% | +1014.3% |
| alltime | all time | -43.0% | +5408.4% | -99.4% | +115.9% | -83.1% | +1014.3% |
Apellis Pharmaceuticals Cash From Financing History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | $2.54 M(-94.0%) | $149.33 M(-2.1%) |
| June 2024 | - | $42.49 M(-60.7%) | $152.53 M(+36.7%) |
| Mar 2024 | - | $108.21 M(-2865.4%) | $111.61 M(-71.7%) |
| Dec 2023 | $394.50 M(+7.9%) | -$3.91 M(-168.1%) | $394.50 M(+3.1%) |
| Sept 2023 | - | $5.75 M(+268.3%) | $382.47 M(-1.0%) |
| June 2023 | - | $1.56 M(-99.6%) | $386.36 M(+1.7%) |
| Mar 2023 | - | $391.11 M(-2552.7%) | $380.06 M(+3.9%) |
| Dec 2022 | $365.66 M(-6.8%) | -$15.95 M(-265.5%) | $365.66 M(-52.2%) |
| Sept 2022 | - | $9.64 M(-303.5%) | $765.56 M(+1.0%) |
| June 2022 | - | -$4.74 M(-101.3%) | $758.05 M(-1.2%) |
| Mar 2022 | - | $376.70 M(-1.9%) | $767.31 M(+95.6%) |
| Dec 2021 | $392.24 M(-43.3%) | $383.96 M(>+9900.0%) | $392.24 M(+2587.5%) |
| Sept 2021 | - | $2.12 M(-53.2%) | $14.60 M(+8.9%) |
| June 2021 | - | $4.53 M(+177.3%) | $13.40 M(-95.4%) |
| Mar 2021 | - | $1.63 M(-74.2%) | $290.54 M(-58.0%) |
| Dec 2020 | $692.18 M | $6.32 M(+582.2%) | $692.18 M(+0.9%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2020 | - | $926.00 K(-99.7%) | $686.07 M(-22.4%) |
| June 2020 | - | $281.67 M(-30.2%) | $884.09 M(+37.4%) |
| Mar 2020 | - | $403.27 M(>+9900.0%) | $643.39 M(+65.6%) |
| Dec 2019 | $388.54 M(+194.6%) | $209.00 K(-99.9%) | $388.54 M(+0.0%) |
| Sept 2019 | - | $198.95 M(+385.7%) | $388.45 M(+105.0%) |
| June 2019 | - | $40.96 M(-72.4%) | $189.46 M(-32.4%) |
| Mar 2019 | - | $148.42 M(>+9900.0%) | $280.10 M(+112.4%) |
| Dec 2018 | $131.90 M(-33.2%) | $115.30 K(-400.3%) | $131.90 M(-57.4%) |
| Sept 2018 | - | -$38.40 K(-100.0%) | $309.83 M(-5.9%) |
| June 2018 | - | $131.60 M(>+9900.0%) | $329.20 M(+66.6%) |
| Mar 2018 | - | $222.70 K(-99.9%) | $197.60 M(+0.1%) |
| Dec 2017 | $197.38 M(+1228.0%) | $178.04 M(+820.8%) | $197.38 M(+920.8%) |
| Sept 2017 | - | $19.33 M | $19.33 M |
| Dec 2016 | $14.86 M(-64.0%) | - | - |
| Dec 2015 | $41.24 M(+119.0%) | - | - |
| Dec 2014 | $18.83 M(+162.9%) | - | - |
| Dec 2013 | $7.16 M | - | - |
FAQ
- What is Apellis Pharmaceuticals annual cash flow from financing activities?
- What is the all time high annual CFF for Apellis Pharmaceuticals?
- What is Apellis Pharmaceuticals annual CFF year-on-year change?
- What is Apellis Pharmaceuticals quarterly cash flow from financing activities?
- What is the all time high quarterly CFF for Apellis Pharmaceuticals?
- What is Apellis Pharmaceuticals quarterly CFF year-on-year change?
- What is Apellis Pharmaceuticals TTM cash flow from financing activities?
- What is the all time high TTM CFF for Apellis Pharmaceuticals?
- What is Apellis Pharmaceuticals TTM CFF year-on-year change?
What is Apellis Pharmaceuticals annual cash flow from financing activities?
The current annual CFF of APLS is $394.50 M
What is the all time high annual CFF for Apellis Pharmaceuticals?
Apellis Pharmaceuticals all-time high annual cash flow from financing activities is $692.18 M
What is Apellis Pharmaceuticals annual CFF year-on-year change?
Over the past year, APLS annual cash flow from financing activities has changed by +$28.84 M (+7.89%)
What is Apellis Pharmaceuticals quarterly cash flow from financing activities?
The current quarterly CFF of APLS is $2.54 M
What is the all time high quarterly CFF for Apellis Pharmaceuticals?
Apellis Pharmaceuticals all-time high quarterly cash flow from financing activities is $403.27 M
What is Apellis Pharmaceuticals quarterly CFF year-on-year change?
Over the past year, APLS quarterly cash flow from financing activities has changed by -$3.20 M (-55.76%)
What is Apellis Pharmaceuticals TTM cash flow from financing activities?
The current TTM CFF of APLS is $149.33 M
What is the all time high TTM CFF for Apellis Pharmaceuticals?
Apellis Pharmaceuticals all-time high TTM cash flow from financing activities is $884.09 M
What is Apellis Pharmaceuticals TTM CFF year-on-year change?
Over the past year, APLS TTM cash flow from financing activities has changed by -$233.14 M (-60.96%)